Community Acquired Pneumonia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The community acquired pneumonia market size was valued at USD 11.85 billion in 2025 and is estimated to grow from USD 12.39 billion in 2026 to reach USD 15.83 billion by 2031, at a CAGR of 5.02% during the forecast period (2026-2031). This report is Segmented by Diagnosis & Treatment (Diagnosis Method, Treatment Type), Pathogen Type (Bacterial, Viral, Fungal, Atypical Pneumonia), Age Group (Infants, Children, Adults, Geriatric), Risk Factors (Chronic Diseases, Smoking, Alcoholism, Weakened Immune System), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Community Acquired Pneumonia Market Trends and Insights

Rising CAP Burden in Older and Immunocompromised Patients

The community-acquired pneumonia market is expanding with the steady rise in elderly and immunocompromised patients who face a higher risk of severe disease and repeat care episodes. A 2025 study in JAMA Network Open showed that adults aged 65 and older carried the heaviest hospitalization burden in the United States, and Streptococcus pneumoniae still caused 14% of cases despite broad vaccine use. A 2025 meta-analysis in the European Journal of Internal Medicine found that 1 in 3 adults hospitalized for CAP died within the following year, with mortality rising from 5% in patients under 65 to 14% in those over 80 and reaching 43% in patients with multiple comorbidities. These outcomes keep demand strong for prevention, early diagnosis, inpatient treatment, and post-discharge management rather than limiting spending to the acute episode alone. The same pattern is reinforcing the role of the community-acquired pneumonia market in long-cycle care planning because transplant recipients, patients on immunosuppressive therapy, and people living with cancer or HIV present with broader pathogen diversity and higher treatment failure risk.

Increasing Antibiotic Innovation for Resistant Respiratory Pathogens

The community-acquired pneumonia market is also being shaped by antibiotic innovation as resistance weakens the reliability of older empiric regimens. A 2026 pooled analysis of the Phase 3 OPTIC and OPTIC-2 trials confirmed that omadacycline remained noninferior to moxifloxacin across a microbiologically diverse CABP population, including patients with pathogens showing reduced fluoroquinolone susceptibility. A 2026 paper in Antibiotics explained that newer agents such as lefamulin and omadacycline were designed to bypass resistance pathways that have reduced the utility of macrolides and fluoroquinolones in lower respiratory infections. Basilea Pharmaceutica started Phase 1 dosing for BAL2420 in 2026, and the added CARB-X funding showed continued support for first-in-class approaches against gram-negative resistance gaps that current approved agents do not fully address. As a result, the community-acquired pneumonia market is moving beyond simple class replacement and toward targeted therapies that can justify premium positioning when standard therapies fail.

Antibiotic Resistance Reducing Efficacy of Standard Regimens

The community-acquired pneumonia market still faces a major barrier because resistance continues to erode the effectiveness of standard first-line regimens. A 2026 cross-sectional study of CAP isolated bacteria documented resistance across beta-lactams, macrolides, and fluoroquinolones, and prior antibiotic exposure closely tracked with those resistance patterns. When first-line therapy becomes less predictable, clinicians escalate more quickly to reserve agents, which increases treatment cost and creates more pressure on stewardship systems. Reimbursement pathways in many countries still move more slowly than resistance patterns, so newer branded drugs do not always gain commercial traction at the same pace as their clinical value. This keeps the community-acquired pneumonia market under pressure because demand for better treatment exists, but access rules, budget limits, and stewardship safeguards still slow broad adoption.

Other drivers and restraints analyzed in the detailed report include:

• Wider Use of Rapid Diagnostics and Imaging in Early CAP Workup
• Broader Pneumococcal and Respiratory Vaccination Adoption
• Delayed or Inaccurate Diagnosis Leading to Non-Optimal Treatment

Segment Analysis

Diagnosis method held 52.83% share in 2025, which made it the largest part of this segmentation and a core spending anchor in the community-acquired pneumonia market. Chest X-ray remains the standard entry point because it is widely available, familiar to clinicians, and cost-efficient in both inpatient and outpatient settings. CT scanning is used more often in complex, recurrent, or immunocompromised presentations where plain imaging does not settle the differential diagnosis. Blood tests such as procalcitonin and C-reactive protein continue to support bacterial versus viral differentiation, while sputum culture remains important for resistance surveillance, and pulse oximetry supports fast severity stratification at triage. These tools keep the community-acquired pneumonia market grounded in established workflows even as higher-value molecular methods move into routine use.

Treatment type is projected to grow at a 5.54% CAGR through 2031, giving it the fastest growth profile within this category and linking more future value to care delivery than to test confirmation alone. Antibiotics still account for the largest share of treatment spending, and newer agents such as omadacycline and lefamulin are widening their role as hospitals respond to resistance risk and formulary needs. Oxygen therapy demand is also rising because more elderly patients present with greater severity and because home oxygen devices now support ambulatory management in selected lower acuity cases. Hospitalization is facing more cost pressure, which encourages wider use of severity scoring, remote follow-up, and ambulatory compatible therapies that reduce avoidable admissions.

Bacterial pneumonia held 60.38% of the community-acquired pneumonia market size in 2025, which kept it well ahead of every other pathogen category. Streptococcus pneumoniae remained the best-known single pathogen, and a 2025 study in JAMA Network Open found that it accounted for 14% of hospitalized CAP cases among older adults in the United States. A 2025 systematic review in the journal Pneumonia reported that non-vaccine serotypes, especially serotype 3, have re-emerged among elderly CAP patients since 2020, which keeps demand in place for broader vaccine coverage and pathogen-specific testing. Gram-negative pathogens such as Klebsiella pneumoniae and resistant Haemophilus influenzae are also taking a larger role in elderly and immunocompromised patients, which supports continued antibiotic innovation against harder-to-treat bacterial disease. For this reason, the community-acquired pneumonia market continues to derive a large share of commercial value from bacterial management even while the pathogen mix is gradually broadening.

Viral pneumonia is forecast to grow at a 6.76% CAGR through 2031, making it the fastest expanding pathogen group in the community-acquired pneumonia market. Better respiratory surveillance since the COVID period has increased the number of viral infections that are specifically identified rather than left in an unspecified CAP category. The spread of multiplex respiratory panels has also improved differentiation between viral, bacterial, and mixed infections, which is changing treatment decisions and epidemiological reporting patterns. Fungal Pneumonia remains smaller in volume but higher in value because immunocompromised patients need specialized diagnosis and treatment, especially for Aspergillus and Pneumocystis jirovecii. Atypical Pneumonia remains clinically important because organisms such as Legionella, Mycoplasma pneumoniae, and Chlamydophila pneumoniae respond poorly to beta lactams, which keeps accurate pathogen identification central to treatment quality in the community acquired pneumonia market.

Complete Report Scope:

• By Diagnosis & Treatment
  • Diagnosis Method
    • Chest X-Ray
    • CT Scan
    • Sputum Culture
    • Blood Tests
    • Pulse Oximetry
  • Treatment Type
    • Antibiotics
    • Oxygen Therapy
    • Hospitalization
    • Supportive Care
• By Pathogen Type
  • Bacterial Pneumonia
  • Viral Pneumonia
  • Fungal Pneumonia
  • Atypical Pneumonia
• By Age Group
  • Infants
  • Children
  • Adults
  • Geriatric Population
• By Risk Factors
  • Chronic Diseases
  • Smoking
  • Alcoholism
  • Weakened Immune System
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 35.63% of the community-acquired pneumonia market share in 2025, which kept it in the lead among all regional groupings. The United States remains the key revenue engine because it combines advanced hospital infrastructure, strong vaccine policy, and active clinical development across therapeutics and diagnostics. ACIP expanded pneumococcal conjugate vaccine eligibility to all adults aged 50 years and older, which strengthened the long-term prevention base for adult disease management. Merck's CAPVAXIVE also added momentum after FDA approval, and the company stated that the vaccine covered 83% to 85% of invasive pneumococcal disease-causing serotypes in adults within this age group. Canada supports steady demand through universal coverage and cost-focused care models, while Mexico adds volume but remains less even in advanced diagnostics penetration.

Europe remained the second largest regional block in the community-acquired pneumonia market, supported by strong stewardship frameworks and steady vaccine and diagnostics demand. France updated outpatient CAP antibiotic guidance in 2025 and limited uncomplicated treatment to a maximum of 7 days, which reinforced faster de-escalation and sharper antibiotic selection. This can limit unit volumes for standard regimens, but it also strengthens the value proposition for rapid respiratory testing and better targeted therapies. Germany, the United Kingdom, Spain, and Italy continue to add meaningful demand across molecular diagnostics, adult vaccination, and hospital-based antibiotic use.

Asia-Pacific is forecast to grow at a 6.04% CAGR through 2031, making it the fastest expanding geography in the community-acquired pneumonia market. India remains important because of the high incidence, and broad public health programs keep both disease burden and treatment access initiatives elevated. A 2025 community study in China found a CAP incidence of 42.1 per 1,000 person-years, with most cases managed in outpatient settings without pathogen confirmation, which points to a large opening for point-of-care diagnostics. The Middle East and Africa, along with South America, still represent earlier-stage opportunities in the community-acquired pneumonia market because better laboratory networks, public procurement, and vaccine access are gradually improving the base for future diagnostics and treatment growth.

List of Companies Covered in this Report:

• Abbott Laboratories
• Abbvie
• APTARION Biotech AG
• AstraZeneca
• Basilea Pharmaceutica Ltd.
• Beckton Dickinson
• bioMérieux S.A.
• Eagle Pharmaceuticals, Inc.
• GlaxoSmithKline
• Hologic
• Melinta Therapeutics LLC
• Merck
• Nabriva Therapeutics plc
• Novartis
• Paratek Pharmaceuticals
• Pfizer
• QuidelOrtho
• Roche
• Sanofi
• Shionogi and Co., Ltd.
• Takeda Pharmaceuticals
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support